Terren Peizer is an entrepreneur and an investor with a particular interest in healthcare, having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder of Catasys, Inc., a publicly traded leader in behavioral and mental health management services. He has also served as the Company’s Chairman of the Board of Directors and CEO since the Company’s inception in 2004. Catasys has contracted with 7 of the 8 largest health plans in the USA that covers 70% of the country's population. Mr. Peizer also is the Founder, Chairman and CEO of NeurMedix, Inc., a biotechnology company with a focus on inflammatory, neurological and neuro-degenerative diseases. NeurMedix’s lead compound NE3107 has shown efficacy in 11 pre-clinical and 6 human studies. These studies resulted in publications in peer-reviewed journals. Mr. Peizer is also the Chairman, CEO and majority shareholder of publicly traded BioVie, Inc. which is the industry leader in the development of two orphan drug candidates for the treatment of the rare liver diseases Ascites and HRS. Mr. Peizer is Chairman of Acuitas Group Holdings, LLC, his personal holding company that is the owner of all of his portfolio company interests, including Catasys, Inc. Through Acuitas, Mr. Peizer also owns Acuitas Capital Group, LLC, an industry leader in investing in publicly traded micro and small capitalization equities, having invested over $1.5 billion directly into portfolio companies. Mr. Peizer has been the largest beneficial shareholder, and has held various senior executive positions with several other publicly-traded growth companies, including Chairman of internationally renowned Cray, Inc., the industry’s leading supercomputer company. Mr. Peizer has a background in finance and capital markets having previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham Lambert. He received his B.S.E. in finance from The Wharton School.